Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits
antihyperuricemic activity by reducing the formation of uric acid. The investigators
conducted an interventional, two-arm, randomized, open label pilot study on patients with
serum urate level ≥ 6.8 mg/dL. Patients were treated with Febuxostat 40 mg Tablets or
Allopurinol 300 mg Tablets once daily dose for 90 days to determine the efficacy and safety
of Febuxostat in comparison with Allopurinol in Hyperuricemic Subjects with or without Gout.